Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor,,in patients with advanced solid tumors

1. Paz-Ares, L.G.
2. Gomez-Roca, C.
3. Delord, J.-P.
4. Cervantes, A.
5. Markman, B.
6. Corral, J.
7. Soria, J.-C.
8. Bergé, Y.
9. Roda, D.
10. Russell-Yarde, F.
11. Hollingsworth, S.
12. Baselga, J.
13. Umana, P.
14. Manenti, L.
15. Tabernero, J.